Radiopharm Theranostics Ltd - Form 6-K Summary
Business Context and Reporting Period
This Form 6-K filing covers the month of June 2026, specifically dated June 3, 2026. The registrant, Radiopharm Theranostics Limited, is a foreign private issuer based in Australia. The filing serves to report a material event regarding the cessation of its securities.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report is an informational notice regarding corporate status rather than a financial performance statement.
Material Changes
The primary material change disclosed is the notification of the cessation of the Company's securities (ticker: RAD) on the Australian Securities Exchange. This indicates the delisting or suspension of trading for the company's shares.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, or outlook for future periods. The document explicitly states that it shall not be deemed "filed" for purposes of the Securities Exchange Act of 1934 and shall not be incorporated by reference into registration statements, except as expressly set forth. The cessation of securities represents a significant contingency affecting investor ability to trade the stock.
Investor Verification Checklist
- Verify the official reason for the cessation of securities (RAD) on the Australian Securities Exchange.
- Confirm the current trading status of the company's shares on other exchanges, if applicable.
- Review the attached Exhibit 99.1 for the full text of the Public Notice.
- Check for subsequent filings regarding potential delisting or bankruptcy proceedings.